Cargando…

It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis

BACKGROUND: Patient-centered care has been proposed as a strategy for improving treatment outcomes in the management of psoriasis and other chronic diseases. A more detailed understanding of patients’ utilities and disutilities associated with treatment features may facilitate shared decision-making...

Descripción completa

Detalles Bibliográficos
Autores principales:	Umar, Nasir, Schöllgen, Ina, Terris, Darcey D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333813/ https://www.ncbi.nlm.nih.gov/pubmed/22536054 http://dx.doi.org/10.2147/PPA.S29285

Ejemplares similares

Disutility Study for Adult Patients with Moderate to Severe Crohn’s Disease
por: Worbes-Cerezo, Melany, et al.
Publicado: (2019)

Disutility associated with cancer screening programs: A systematic review
por: Li, Lin, et al.
Publicado: (2019)

Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events
por: Hall, F., et al.
Publicado: (2019)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
por: Jin, Joy Q, et al.
Publicado: (2023)

Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration
por: Omidvari, Amir-Houshang, et al.
Publicado: (2021)

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
por: Kivelevitch, Dario, et al.
Publicado: (2019)

Outcomes associated with matching patients' treatment preferences to physicians' recommendations: study methodology
por: Umar, Nasir, et al.
Publicado: (2012)

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment
por: Lu, Yuqiong, et al.
Publicado: (2023)

Therapy of moderate and severe psoriasis
por: Claes, Christa, et al.
Publicado: (2006)

Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China
por: Hu, Shanlian, et al.
Publicado: (2023)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
por: Pinter, Andreas, et al.
Publicado: (2019)

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2009)

Better Informing Decision Making with Multiple Outcomes Cost-Effectiveness Analysis under Uncertainty in Cost-Disutility Space
por: McCaffrey, Nikki, et al.
Publicado: (2015)

Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China
por: McEwan, Phil, et al.
Publicado: (2022)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
por: Salgado-Boquete, Laura, et al.
Publicado: (2021)

Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance
por: Wu, Albert G., et al.
Publicado: (2020)

Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017)

Quantifying the impact of taking medicines for primary prevention: a time-trade off study to elicit direct treatment disutility in the UK
por: Thompson, Alexander, et al.
Publicado: (2023)

Income Trajectories and Subjective Well-Being: Linking Administrative Records and Survey Data
por: Schöllgen, Ina, et al.
Publicado: (2019)

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
por: Jiang, Yuxiong, et al.
Publicado: (2023)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

Socioeconomic status and health in the second half of life: findings from the German Ageing Survey
por: Schöllgen, Ina, et al.
Publicado: (2010)

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007)

Biological therapies in moderate and severe psoriasis: perspectives and certainties
por: Constantin, MM, et al.
Publicado: (2014)

Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2015)

THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS: A BIOLOGIC REVOLUTION
por: Skillen, LA, et al.
Publicado: (2018)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Effects of methotrexate and etanercept treatment in moderate and severe psoriasis
por: Benites, Elizabeth, et al.
Publicado: (2022)

Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis
por: Suárez-Fariñas, Mayte, et al.
Publicado: (2012)

It's always about numerators and denominators (N/D)
por: Knottnerus, J. André, et al.
Publicado: (2020)

Always Online? Internet Addiction and Social Impairment in Psoriasis across Germany
por: Schielein, Maximilian Christian, et al.
Publicado: (2020)

Compositional Features of Distinct Microbiota Base on Serum Extracellular Vesicle Metagenomics Analysis in Moderate to Severe Psoriasis Patients
por: Chang, Chih-Jung, et al.
Publicado: (2021)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Kimball, Alexa B., et al.
Publicado: (2021)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_iald0doe0qdnaa9vheo1j1kc8n